Meeder Advisory Services Inc. Purchases Shares of 1,884 Medpace Holdings, Inc. $MEDP

Meeder Advisory Services Inc. purchased a new stake in Medpace Holdings, Inc. (NASDAQ:MEDP) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 1,884 shares of the company’s stock, valued at approximately $998,000.

A number of other institutional investors also recently bought and sold shares of MEDP. BlackRock Inc. purchased a new position in shares of Medpace in the 2nd quarter valued at about $1,323,047,000. AQR Capital Management LLC lifted its stake in Medpace by 65.1% during the third quarter. AQR Capital Management LLC now owns 1,025,410 shares of the company’s stock worth $518,170,000 after purchasing an additional 404,226 shares during the last quarter. Arrowstreet Capital Limited Partnership boosted its holdings in Medpace by 205.8% in the third quarter. Arrowstreet Capital Limited Partnership now owns 314,150 shares of the company’s stock valued at $161,523,000 after purchasing an additional 211,411 shares in the last quarter. Franklin Resources Inc. boosted its holdings in Medpace by 158.6% in the fourth quarter. Franklin Resources Inc. now owns 299,472 shares of the company’s stock valued at $168,198,000 after purchasing an additional 183,645 shares in the last quarter. Finally, Norges Bank purchased a new position in Medpace in the fourth quarter valued at approximately $102,156,000. 77.98% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Medpace

In other Medpace news, Director Cornelius P. Mccarthy III sold 1,140 shares of Medpace stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $605.37, for a total value of $690,121.80. Following the transaction, the director directly owned 12,275 shares in the company, valued at approximately $7,430,916.75. The trade was a 8.50% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, VP Susan E. Burwig sold 7,500 shares of the company’s stock in a transaction dated Tuesday, July 28th. The shares were sold at an average price of $600.00, for a total transaction of $4,500,000.00. Following the completion of the sale, the vice president directly owned 62,984 shares of the company’s stock, valued at $37,790,400. The trade was a 10.64% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 67,195 shares of company stock worth $37,989,998 in the last quarter. 20.50% of the stock is currently owned by company insiders.

Medpace Trading Up 3.0%

MEDP stock opened at $608.27 on Thursday. The company has a market capitalization of $16.98 billion, a P/E ratio of 35.65, a PEG ratio of 2.63 and a beta of 1.15. Medpace Holdings, Inc. has a twelve month low of $373.00 and a twelve month high of $677.90. The business has a 50 day simple moving average of $544.34 and a 200-day simple moving average of $491.59.

Medpace (NASDAQ:MEDP) last announced its earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.98 by $0.27. The business had revenue of $707.33 million for the quarter, compared to analyst estimates of $689.51 million. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The company’s revenue for the quarter was up 17.2% compared to the same quarter last year. During the same period last year, the firm posted $3.10 earnings per share. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Research analysts predict that Medpace Holdings, Inc. will post 17.54 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts have recently weighed in on the stock. Robert W. Baird boosted their price objective on shares of Medpace from $547.00 to $624.00 and gave the stock a “neutral” rating in a research report on Friday, July 24th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and set a $535.00 price target on shares of Medpace in a research note on Thursday, July 23rd. Leerink Partners set a $620.00 price objective on shares of Medpace in a research note on Thursday, July 23rd. Barclays set a $600.00 price objective on Medpace in a report on Thursday, July 23rd. Finally, Weiss Ratings upgraded Medpace from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, August 12th. Three equities research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Medpace presently has a consensus rating of “Hold” and a consensus target price of $584.18.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.